Trastuzumab Completed Phase 2 Trials for Prostate Cancer Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00005857Trastuzumab and Docetaxel in Treating Patients Who Have Metastatic Prostate Cancer That Is Refractory to Hormone Therapy
NCT00003740Trastuzumab in Treating Patients With Prostate Cancer